title: Weight Loss Randomized Intervention Trials in Female Cancer Survivors.
abstract: Purpose Observational study evidence has associated overweight/obesity with decreased survival in women with breast cancer and with several other cancers. Although full-scale, definitive weight loss adjuvant intervention trials with cancer end points remain to be conducted, a number of randomized controlled trials have evaluated weight loss interventions in survivors of cancer in women. Findings from these trials in breast, endometrial, and ovarian cancer are reviewed. Methods A systematic review of randomized controlled clinical trials evaluating weight loss interventions was updated (for studies published 2013 to 2016), and clinical trials registers were searched for ongoing trials. Results Six new randomized trials in breast cancer survivors and two randomized trials in endometrial cancer survivors were identified. Evidence from these trials and the 10 earlier randomized trials in female cancer survivors provide support for the feasibility of recruiting women closer to the cancer diagnosis and efficacy for achieving weight loss, in particular with telephone-based interventions, and have identified the challenge of achieving significant weight loss in African American cancer survivors and of maintaining weight loss in any cancer survivor group. Seven ongoing randomized trials are evaluating the influence of weight loss interventions on cancer end points (five in breast cancer, one in ovarian cancer, and one in endometrial cancer). Conclusion After a decade of preliminary studies, ongoing randomized, controlled clinical trials will potentially provide definitive assessment of whether weight loss can improve breast cancer clinical outcome. Longer-term interventions (> 2 years' duration) may be needed to optimize weight loss maintenance and any potential benefits on cancer end points.
authors.affiliation: Rowan T. Chlebowski, Harbor-University of California, Los Angeles Medical Center, Torrance, CA; and Marina M. Reeves, The University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Rowan T
authors.initials: RT
authors.lastname: Chlebowski
authors.affiliation: Rowan T. Chlebowski, Harbor-University of California, Los Angeles Medical Center, Torrance, CA; and Marina M. Reeves, The University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Marina M
authors.initials: MM
authors.lastname: Reeves
mesh_terms: D001943:Breast Neoplasms / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control*; D005260:Female; D015438:Health Behavior; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D017741:Survivors; D015431:Weight Loss